As a continuation of their research on the development of hepcidin production inhibitors for treating anemia of chronic disease (ACD), a series of new 4,6-disubstituted indazole compounds were designed, synthesized and evaluated as inhibitors of the above enzyme by Fukuda et al. [107]. The gene discussed is HAMP; the disease is granular corneal dystrophy type II.